Do you want to read an article? Please log in or register.
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Interstitial Lung Disease
PHARMA NEWS
Related content
PHARMA NEWS
Interstitial Lung Disease
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
doi: 10.1056/NEJMoa1903076
RECOMMENDED
Interstitial Lung Disease
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
N Engl J Med.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators.
doi: 10.1056/NEJMoa1903076.
RECOMMENDED
Interstitial Lung Disease
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ann Rheum Dis.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O, SENSCIS trial investigators
doi: 10.1136/annrheumdis-2020-217331.
RECOMMENDED
Further Publications
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM, SENSCIS trial investigators.
doi: 10.1016/S2213-2600(20)30330-1
SPECIAL REPORT
Interstitial Lung Disease
OFEV® extended indication offers new hope for patients with SSc-ILD
CoughInterstitial Lung Disease
Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases
Respirology.
Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ
doi: 10.1111/resp.13084.
RECOMMENDED
Interstitial Lung DiseasePneumonia
[New developments in systemic sclerosis-associated interstitial lung disease]
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Rev Med Suisse
Humair G, Daccord C, Beigelman-Aubry C, Lazor R
RECOMMENDED
Interstitial Lung Disease
Systemic sclerosis-associated interstitial lung disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Perelas A, Silver RM, Arrossi AV, Highland KB
doi: 10.1016/S2213-2600(19)30480-1.
RECOMMENDED
Systemic Sclerosis
Independent association between occupational exposure and decline of forced vital capacity in systemic sclerosis (SSc): a multicenter recruitment retrospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest
Thoreau B, Eustache M, Fievet A, Lasfargues G, Plantier L, Diot E
doi: 10.1016/j.chest.2021.11.009